Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1992-12-31
|
| pubmed:abstractText |
A total of 36 patients with advanced non-small-cell lung cancer (NSCLC) were treated with a combination of 5-day continuous i.v. infusion of cisplatin (25 mg/m2 daily), bolus infusion of vindesine (3 mg/m2) on days 1 and 8, and s.c. injection of recombinant human granulocyte-colony-stimulating factor (2 micrograms/kg daily) on days 6-21. Treatment was repeated every 3-4 weeks. Responding patients with stage IIIA or IIIB disease received chest radiation therapy (50-60 Gy) after this treatment. One complete response and 23 partial responses were observed, for an overall response rate of 66.7% (24/36; 95% confidence limits, 51.3%-82.1%). The median duration of response was 5.7 months and the median overall survival was 10.1 months. WHO grade 3 or 4 leukopenia and neutropenia occurred in 22 (61%) and 27 (75%) patients, respectively, but the mean duration of leukopenia (< 2,000/mm3) and neutropenia (< 1,000/mm3) was 3.4 and 3.5 days, respectively, and there was no instance of life-threatening infection. Thrombocytopenia and anemia of grade 3 or 4 occurred in 28% and 36% of our subjects, respectively. Grade 2 nausea and vomiting occurred in 47% of the patients. Elevated serum creatinine levels (> 1.5 mg/dl) were observed in 3 (8%) of the 36 patients. One patient died of acute renal failure induced by hemorrhage of a gastric ulcer. This regimen is effective in the treatment of NSCLC and further studies of this combination are warranted.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0344-5704
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
31
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
81-4
|
| pubmed:dateRevised |
2006-4-24
|
| pubmed:meshHeading |
pubmed-meshheading:1280537-Actuarial Analysis,
pubmed-meshheading:1280537-Adult,
pubmed-meshheading:1280537-Aged,
pubmed-meshheading:1280537-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:1280537-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:1280537-Cisplatin,
pubmed-meshheading:1280537-Combined Modality Therapy,
pubmed-meshheading:1280537-Drug Administration Schedule,
pubmed-meshheading:1280537-Female,
pubmed-meshheading:1280537-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:1280537-Humans,
pubmed-meshheading:1280537-Leukopenia,
pubmed-meshheading:1280537-Lung Neoplasms,
pubmed-meshheading:1280537-Male,
pubmed-meshheading:1280537-Middle Aged,
pubmed-meshheading:1280537-Neutropenia,
pubmed-meshheading:1280537-Recombinant Proteins,
pubmed-meshheading:1280537-Survival Analysis,
pubmed-meshheading:1280537-Vindesine
|
| pubmed:year |
1992
|
| pubmed:articleTitle |
Phase II study of cisplatin as a 5-day continuous infusion with vindesine plus recombinant human granulocyte-colony-stimulating factor in the treatment of advanced non-small-cell lung cancer.
|
| pubmed:affiliation |
Division of Thoracic Disease, Tochigi Cancer Center, Japan.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|